ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1527

Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison

Laura Sawyer1, Stacey Chang1, Alex Diamantopoulos2 and Fred Dejonckheere3, 1Symmetron Limited, London, United Kingdom, 2Symmetron Limited, Herts, United Kingdom, 3F. Hoffmann-La Roche, Basel, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, DMARDs, Early Rheumatoid Arthritis, meta-analysis and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the effectiveness of tocilizumab (TCZ) compared with other traditional and biologic disease-modifying antirheumatic drugs (tDMARDs and bDMARDs), alone and in combination, in adult patients with moderate to severe ERA who have not been treated with methotrexate (MTX) or bDMARDs.

Methods: A literature review was undertaken to identify randomized controlled trials (RCTs) of tDMARDs and bDMARDs in patients with ERA (duration, <3 years) that reported efficacy outcomes, including the proportions of patients achieving American College of Rheumatology (ACR) scores of 20, 50, 70, and 90 and disease activity score (DAS28)–defined remission (DAS28 <2.6). Study data were pooled using Bayesian network meta-analysis techniques. For ACR response, data were analyzed using a fixed-effects (FE) ordered probit model, which makes efficient use of ordered categorical data and guarantees coherent prediction of multinomial response probabilities. For DAS remission, data were analyzed with an FE binomial logit model. The analysis included only results for treatments in licensed doses. Sensitivity analyses tested the effects of grouping treatments by class and broadening and narrowing inclusion criteria.

Results: We included 16 RCTs of tDMARDs (MTX, sulfasalazine [SSZ], hydroxychloroquine [HCQ]), bDMARDs (abatacept [ABT], adalimumab [ADA], etanercept [ETN], infliximab [IFX], golimumab [GOL], and TCZ), and tofacitinib (Tofa). Results indicate that all bDMARDs + MTX, triple tDMARD therapies, and TCZ and Tofa in monotherapy significantly increased response across all ACR categories versus MTX. (Figure). Probabilities of ACR response to bDMARDs + MTX were broadly similar, with no significant differences between agents. Probabilities of ACR response to bDMARDs in monotherapy were more varied, with a trend toward higher values for Tofa and TCZ than for ETN or ADA. Only a subset of studies reported DAS remission. Results show that treatment with Tofa or any bDMARD (± MTX) except ADA alone improved the likelihood of DAS remission versus MTX. TCZ (± MTX) generated the highest probability of remission among bDMARD agents and was significantly more effective than all other bDMARDs (± MTX) and Tofa. Results across both outcomes were robust to alternative grouping of interventions and to change in the inclusion criteria.

Conclusion: Based on ACR response, the expected efficacy of bDMARDs + MTX, Tofa and TCZ monotherapy, and triple tDMARD therapy appears comparable in early RA. TCZ and Tofa in monotherapy are more effective than ADA alone and are likely to be more effective than ETN alone. TCZ ± MTX is expected to have the highest probability of generating DAS.

 


Disclosure:

L. Sawyer,

F. Hoffmann-La Roche,

5;

S. Chang,

F. Hoffmann-La Roche,

5;

A. Diamantopoulos,

F. Hoffmann-La Roche,

5;

F. Dejonckheere,

F. Hoffmann-La Roche,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-biologic-treatments-in-early-active-rheumatoid-arthritis-an-indirect-comparison/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology